Cardiovascular residual risk assessment in patients undergoing therapy: A combined structural and functional approach

Current Cardiovascular Imaging Reports

Volumn 2, Issue 6, 2009, Pages 405-409

  Hecht, Harvey S ^a   Naghavi, Morteza ^b  

^a LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81055154896     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-009-0051-4     Document Type: Article

References (26)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-1389.
2. Giraldez RR, Giugliano RP, Mohanavelu S, et al.: Baseline low density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol 2008, 52: 914-920.
3. Sacks FM, Moyé LA, Davis BR, et al.: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation 1998, 97: 1446-1452.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339: 1349-1357.
5. LaRosa JC, Grundy SM, Kastelein JJP, et al.: Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007, 100: 747-752.
6. Pedersen TR, Faergeman O, Kastelein JJP, et al.: for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA 2005, 294: 2437-2445.
7. Friedewald VE, Ballantyne CM, Davidson MH, et al.: The Editor's Roundtable: Lipid management beyond statins-reducing residual cardiovascular risk. Am J Cardiol 2008, 102: 559-567.
8. Espeland MA, Craven TE, Riley WA, et al.: Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 1996, 27: 480-485.
9. Lakoski SG, Greenland P, Wong ND, et al.: Coronary artery calcium scores and risk for cardiovascular events in women classified as "low risk" based on Framingham risk score. The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2007, 167: 2437-2442.
10. Detrano R, Guerci AD, Carr JJ, et al.: Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358: 1336-1345.
11. Becker A, Leber A, Becker C, Knez A: Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. Am Heart J 2008, 155: 154-160.
12. Raggi P, Davidson M, Callister TQ, et al.: Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic post-menopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation 2005, 112: 563-571.
13. Arad Y, Spadaro LA, Roth M, et al.: Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. The St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005, 46: 166-172.
14. Schmermund A, Achenbach S, Budde T, et al.: Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months. A multicenter, randomized, double-blind trial. Circulation 2006, 113: 427-437.
15. Raggi P, Callister TQ, Shaw LJ: Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004, 24: 1-7.
16. Raggi P, Callister TQ, Shaw LJ: Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol 2004, 24: 1272-1277.
17. Callister TQ, Cooil B, Raya S, et al.: Coronary artery disease: improved reproducibility of calcium scoring with an electron beam-CT volumetric method. Radiology 1998, 208: 807-814.
18. Kim WY, Astrup AS, Stuber M, et al.: Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation 2007, 115: 228-235.
19. Corti R, Fuster V, Fayad ZA, et al.: Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002, 106: 2884-2887.
20. Briley-Saebo KC, Shaw PX, Mulder WJ, et al.: Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008, 117: 3206-3215.
21. Kircher MF, Grimm J, Swirski FK, et al.: Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation 2008, 117: 388-395.
22. Nahrendorf M, Zhang H, Hembrador S, et al.: Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117: 379-387.
23. Pundziute G, Schuijf JD, Jukema JW, et al.: Head-to-head comparison of coronary plaque evaluation between multislice computed tomography and intravascular ultrasound radiofrequency data analysis. J Am Coll Cardiol Intv 2008, 1: 176-182.
24. Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction testing and clinical relevance. Circulation 2007, 115: 1285-1295.
25. Ahmadi N, Hajsadeghi F, Gul K, et al.: Relations between digital thermal monitoring of vascular function, the Framingham risk score, and coronary artery calcium score. J Cardiovasc Comp Tomog 2008, 2: 382-388.
26. Koenig W, Khuseyinova N, Löwel H, et al.: Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004, 110: 1903-1908.